Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Relx confirms guidance after 'strong' start to the year

(Sharecast News) - Relx reiterated its full-year outlook on Thursday, after the analytics provider said the year had got off to a "strong" start. The global firm, which provides information-based analytics and decision tools to professionals businesses, said underlying revenues had grown in all four of its divisions.

In risk, which accounts for 34% of group sales, strong revenue growth had been driven largely by financial crime compliance and by digital fraud and identity.

In its scientific, technical and medical unit, Relx's second-biggest division, the jump in revenues was attributed to "the evolution of the business mix".

Relx said: "The full-year outlook is unchanged.

"We continue to see positive momentum across the group, and we expect another year of strong underlying growth in revenue and adjusted operating profit, as well as strong growth in adjusted earnings per share on a constant currency basis."

As at 0830 BST, the blue chip's London-listed shares were up 1% at 3,965p. The company, which employs around 36,000 people across more than 180 countries, is also listed in Amsterdam and New York.

Relx, formerly known as Reed Elsevier, was updating investors ahead of its annual general meeting. Its year end is 31 December 2025.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.